ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1354	National Cancer Institute	Html	null	Melanoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of melanoma.			CLICK HERE
1391	National Cancer Institute	Html	en	Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Wilms tumor.	wilms tumors 0.503727 wilms tumor 0.905843 Wilms tumor development 0.5254 Wilms tumor genetics 0.517912 Wilms Tumor Study-5 0.477443 familial Wilms tumour 0.446601 favorable-histology wilms tumor 0.511105 stage II Wilms 0.439212 unilateral Wilms tumor 0.553115 Wilms tumor patients 0.529584 favorable histology Wilms 0.460427 bilateral Wilms patients 0.460054 Tumor Study Group 0.595101 contralateral Wilms tumor 0.495745 Wilms tumor-Aniridia syndrome 0.439108 preoperative wilms tumor 0.505524 bilateral wilms tumor 0.635902 stromal-type Wilms tumor 0.516983 Wilms tumor surveillance 0.49553 beckwith-wiedemann syndrome 0.43423 inoperable Wilms tumor 0.526248 Group/National Wilms Tumor 0.47873 Low-risk Wilms Tumor 0.474612 histology Wilms tumors 0.433526 Wilms Tumor Study 0.723902	Wilms tumor screening 0.479856 wilms tumor rupture 0.501052 et al. 0.499553 wilms tumor predisposition 0.521351 histology Wilms tumor 0.504567 Wilms tumours 0.453209 COG Wilms tumor 0.518219 SIOP Wilms Tumor 0.504401 Wilms tumour 0.50015 bilateral Wilms tumor. 0.45063 Pediatr Blood Cancer 0.440629 wilms tumor suppressor 0.492641 nonsyndromic Wilms tumor 0.493832 Metachronous bilateral Wilms 0.434751 National Wilms Tumor 0.736085 Med Genet 0.447601 Abstract 0.531043 Clin Oncol 0.453706 familial Wilms tumor. 0.444435 Wilms tumor locus 0.521817 Familial Wilms tumor 0.495658 non-WT1-syndromic Wilms tumor 0.488494 Wilms Tumor Study-3 0.478135 Wilms tumor susceptibility 0.497583	CLICK HERE
1473	National Cancer Institute	Html	en	Gallbladder Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of gallbladder cancer.	similar median OS 0.628591 intact organ function 0.622839 PDQ cancer information 0.730699 extrahepatic bile duct 0.642047 standard surgical procedure 0.635592 Systemic chemotherapy 0.571595 lymphatic tissue 0.570673 biliary obstruction 0.585733 cancer information summary 0.709899 breast cancer prevention 0.628762 hematologic toxic effects 0.620759 delayed recurrences 0.576123 gallbladder cancer. 0.68322 median overall survival 0.632156 surgical specimen 0.573532 wedge resection 0.601072 liver tissue 0.572719 port sites 0.635991 single institution 0.570884 metastatic gallbladder cancer 0.742217 NCI’s PDQ 0.589794 NCI PDQ cancer 0.658789 lymph nodes 0.686365 consecutive surgical patients 0.660543	laparoscopic removal 0.566309 N2 lymph node 0.694743 gallbladder cancer 0.941749 transhepatic biliary drainage 0.640041 node positive tumors 0.650245 single-agent gemcitabine 0.568199 hepatoduodenal ligament 0.573622 surgical intervention. 0.574213 muscle layer 0.568687 routine gallbladder operation 0.744072 unsuspected cancer 0.606476 phase III study 0.612031 5-year survival 0.582018 advanced biliary cancers 0.636965 PDQ documents 0.58963 platinum agents 0.566154 gallbladder bed 0.684231 transient partial remissions 0.621529 node negative tumors 0.647847 adequate performance status 0.625607 unsuspected gallbladder cancer 0.785275 Long-term disease-free survival 0.641402 pathologic examination 0.580848 Kaplan-Meier estimates 0.57231	CLICK HERE
1528	National Cancer Institute	Html	en	Ovarian Low Malignant Potential Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.	currently used treatment 0.491433 treatment 0.80031 abnormal cells 0.591776 cancer treatment 0.491469 ovaries 0.553108 abdomen 0.566902 body cavity 0.495458 NCI-supported cancer 0.497228 tissue 0.516419 cancer cells 0.493195 body 0.515176 Cancer Information Service 0.489344 low malignant potential 0.507879 PDQ cancer information 0.620272 clinical trial search 0.566415 uterus 0.498028 treatment clinical trials 0.555055 National Cancer Institute 0.572253 clinical trials 0.964888 tumor cells 0.695966 Treatment Options section 0.484079 cancer information summary 0.567078 clinical trial 0.741404 new treatment 0.564234	disease 0.554973 malignant potential tumor 0.900634 new treatments 0.489278 patients 0.603036 earlier clinical trials 0.497766 clinical trials database 0.496798 peritoneal cavity 0.517264 Potential Tumors Treatment 0.491558 treatment clinical trial 0.511947 PDQ Adult Treatment 0.504736 NCI PDQ cancer 0.507801 ovary 0.536161 cancer clinical trials 0.578107 tests 0.498811 stage 0.7416 malignant potential tumors 0.621847 fallopian tubes 0.57444 treatment options 0.549139 Treatment Editorial Board 0.533517 cancer information summaries 0.487894 comprehensive cancer information 0.488381 cancer 0.721628 standard treatment 0.552748	CLICK HERE
1712	National Cancer Institute	Html	en	Antioxidants and Cancer Prevention	A fact sheet about antioxidants, substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer.	Nutrition Intervention Trial 0.501895 esophageal cancer 0.494202 cancer prevention 0.637226 dietary antioxidant supplements 0.628093 Retinol Efficacy Trial 0.539912 antioxidants 0.567107 supplementation 0.636543 beta-carotene supplementation 0.609246 vitamin E supplementation 0.519408 randomized controlled trials 0.504401 trial 0.573618 daily supplementation 0.567334 lung cancer 0.591669 Alpha-Tocopherol/Beta-Carotene Cancer Prevention 0.499391 Health Study 0.544001 free radical damage 0.506138 beta-carotene supplements 0.507967 National Cancer Institute 0.710208 dietary antioxidants 0.513132 beta carotene 0.496454 cardiovascular disease 0.651531 Cancer Prevention Study 0.537001 Vitamin E Cancer 0.510878	free radicals 0.842716 exogenous antioxidants 0.527581 Cancer Prevention Trial 0.559457 alpha-tocopherol supplementation 0.518828 gastric cancer 0.506898 skin cancer incidence 0.521176 antioxidant vitamins 0.499147 cancer development 0.495835 total cancer incidence 0.520828 randomized controlled trial 0.509347 antioxidant supplementation 0.554893 antioxidant supplements 0.754474 prostate cancer 0.575846 effects 0.540142 all-cause mortality 0.510888 et al 0.922404 New England Journal 0.537799 cancer risk 0.507337 lung cancer incidence 0.528817 cancer 0.94983 incidence 0.572134 cancer incidence 0.567041 long-term beta-carotene supplementation 0.539474	CLICK HERE
1898	National Cancer Institute	Html	es	Tratamiento del cáncer de recto (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de recto.	pequeña porción 0.344303 siguientes procedimientos 0.488361 estadio iv 0.798609 siguientes aspectos 0.39574 ecografía transrectal 0.363875 siguientes tipos 0.371556 tumor causa obstrucción 0.365452 rayos x 0.358514 estadio ivb 0.576844 enlace drugs approved 0.373438 menor cantidad 0.340782 escáner tep 0.363457 ondas sonoras 0.360161 estadio iva 0.572549 información ayuda 0.344729 recto forma 0.870609 quimioterapia sistémica 0.542487 proteína llamada factor 0.366746 National Cancer Institute 0.340908 recto recidivante 0.833054	cáncer.ampliar colonoscopia 0.503991 Instituto Nacional 0.373842 estadio iiia 0.782206 PDQ Tratamiento 0.378717 antecedentes familiares 0.362005 estadio iiic 0.75767 estadio iiib 0.767428 estadio iia 0.790435 siguientes problemas 0.397252 estadio iic 0.78747 células cancerosas.El bevacizumab 0.411094 Physician Data Query 0.44928 Malestar abdominal 0.370918 Rectal Cancer 0.347301 crecer.El ziv-aflibercept 0.34268 antígeno carcinoembrionario 0.591724 sección cáncer 0.945618 ano).ampliar extirpación 0.350725 siguientes sumarios 0.436031 siguientes pruebas 0.396087	CLICK HERE
2041	National Cancer Institute	Html	es	Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga.	antecedentes familiares 0.40081 Schistosoma haematobium 0.417111 Visuals Online 0.357081 PDQ Exámenes 0.503031 Physician Data Query 0.696072 Estados Unidos 0.406708 túbulos renales 0.432914 prevención revisa 0.368302 sistema urinario masculino 0.518469	largo plazo 0.406946 vejiga almacena 0.840919 información ayuda 0.374743 biopsia.ampliar cistoscopia 0.431465 National Cancer Institute 0.400139 siguientes riesgos 0.364163 pelvis renal 0.934476 Instituto Nacional 0.483729	CLICK HERE
14599	National Cancer Institute	Html	en	PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck Cancer	Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection.	fewer neck dissections 0.480753 different PET-imaging systems 0.416156 trial 0.383529 surgical dissection 0.49691 surgery group 0.546725 equivocal response 0.373027 main goal 0.370069 standard first-line therapy 0.446339 2-year overall survival 0.421723 results 0.372041 PET-CT–guided surveillance 0.384586 PET-CT group 0.386097 advanced squamous cell 0.578344 standardized PET imaging 0.419169 heterogeneous study population 0.413368 2,200-per-patient cost savings 0.413451 study groups 0.42202 patients 0.610711 metabolic abnormalities 0.37096 Dr. Malik 0.419332 health care costs 0.414997 lymph nodes 0.375275 overall survival rates 0.55552 surveillance group 0.491325	chemoradiation 0.396529 Shakun Malik 0.372291 nodal metastases 0.375714 positron-emission tomography 0.373068 magnetic resonance imaging 0.431542 Cancer Research UK 0.422638 Technology Assessment Programme 0.42519 United States 0.41309 N3 disease 0.374897 fewer operations 0.382441 randomized controlled PET-NECK 0.429823 PET-CT imaging 0.485125 advanced imaging techniques 0.434786 neck dissection 0.819668 PET-CT surveillance 0.497223 neck dissection patients 0.544115 Hisham Mehanna 0.370962 long-term results 0.369928 trial results 0.371832 United Kingdom 0.369679 cancer treatment centers 0.428263 substantial complications 0.369604 New England Journal 0.442645 clinical usefulness 0.371858	CLICK HERE
15487	National Cancer Institute	Html	en	Seeking Cancer Clues in Blood, Researchers Explore Exosomes	A feature-length Research Update article about exploring ways to use vesicles known as exosomes to develop new clinical tests and tools for patients with cancer.	Dr. Alvarez 0.382039 exciting preliminary study 0.288255 Hector Alvarez 0.230222 organ-specific metastases 0.263438 research 0.34419 unneeded proteins 0.218149 cancer-associated genetic alterations 0.292328 Ph.D. 0.232319 reliable diagnostic biomarkers 0.286894 pancreatic tumors 0.316162 tumor-derived exosomes 0.435098 liver metastases 0.261607 distant sites 0.270026 David Lyden 0.230954 potential source 0.27056 potentially debilitating surgery 0.288289 researchers 0.33374 exosomal DNA 0.235697 generally reliable source 0.276449 ultimate goal 0.288377 liquid biopsy tests 0.276523 Dr. Lyden 0.452577 cell-free DNA 0.302958 Weill Cornell Medicine 0.277332 coauthor Bruno Costa-Silva 0.277568	different cells 0.270221 exosome-derived DNA 0.320829 potential clinical application 0.294125 primary cancer 0.228119 lung metastases 0.261657 cancer cells 0.736815 accompanying editorial 0.30439 Trinity College Dublin 0.290697 primary tumor cells 0.384123 release exosomes 0.30546 originating cells 0.294925 high-quality DNA 0.233017 metastases 0.284855 distant locations 0.221908 diagnostic blood test 0.298912 exosomes 0.914671 Cancer Research 0.263148 pancreatic cancer cells 0.436342 specific cells 0.275707 MD Anderson Cancer 0.353274 clinical tools 0.317657 breast cancer 0.228037 genetic changes 0.218672 tumor DNA 0.385381	CLICK HERE
17292	National Cancer Institute	Html	es	Sangrado y moretones (trombocitopenia)	Información y consejos para controlar el sangrado y los moretones, los cuales son efectos secundarios del tratamiento del cáncer.	lip balm 0.762223		CLICK HERE